亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Suppression of Allergic Lung Inflammation and Hyperactivity

技术优势: Non toxic Water soluble Effectiveness at nanomole level Enhanced therapeutic potential

详细技术说明: Myrisolyated alanine-rich C kinase substrate (MARCKS), a substrate of protein kinase C, is a key regulatory molecule controlling mucus granule secretion by airway epithelial cells as well as directed migration of leukocytes, stem cells, and fibroblasts. Previous research has shown that the non-canonical function of MARCKS relies on its ability to stay in membrane to trap PIP2 in allergic asthma. This activity is lost if MARCKS is phosphorylated and dissociated from the membrane. UC Davis researchers have shown elevated phosphorylated MARCKS associated with human and animal asthma tissues. Thus, inhibiting MARCKS signaling activity can potentially be therapeutic points of intervention for treating asthma. Researchers at the University of California, Davis have developed a novel non-toxic and water soluble peptide which targets MARCKS’ phosphorylation site domain and inhibits MARCKS phosphorylation and its activity. UC Davis researchers have shown that this novel peptide is able to suppress allergic lung asthma symptoms including airway Inflammation, hyper-reactivity and mucous cell metaplasia in mice models in vivo. The peptide is effective at a nanomole level with no cytotoxicity to normal as well as asthmatic airway epithelia. Mechanistically, this peptide can reduce PIP3 pools and phospho-MARCKS levels through trapping membrane PIP2, leading to blocking PIP3-mediated signaling networks such as PI3k/AKT, PDK1, GRP1 and ARNO signaling.

*Abstract: Phosphorylated Myrisolyated Alanine-rich C Kinase Substrate (MARCKS) is elevated in human and animal asthmatic tissues. In addition, unphosphorylated MARCKS is also the key molecule to trap PIP2 and to interact with PI3K and Src at cell membrane. Researchers at the University of California, Davis have developed a novel, non-toxic, and water soluble peptide, targeting MARCKS’ phosphorylation site domain, that inhibits MARCKS activity and retains PIP2 pool to suppress PIP3 production. As a result, the peptide treatment is capable of suppression of allergic lung inflammation and hyper-reactivity.

*Principal Investigation: Name: Ching-Hsien Chen
Department:

Name: Chen-Chen Lee
Department:

Name: Reen Wu
Department:

其他

Additional Technologies by these Inventors

Tech ID/UC Case

24415/2014-228-0

Related Cases

2014-228-0

欲了解更多信息，请点击这里